MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.98
+0.33
+0.98%
Closed 17:51 03/03 EST
OPEN
33.22
PREV CLOSE
33.65
HIGH
34.90
LOW
32.53
VOLUME
64.83K
TURNOVER
--
52 WEEK HIGH
60.00
52 WEEK LOW
2.940
MARKET CAP
140.85M
P/E (TTM)
-3.3494
1D
5D
1M
3M
1Y
5Y
Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
GlobeNewswire · 2d ago
Global Bi-Specific Antibodies Therapy Market 2020 Driving Factors, Industry Growth, Key Vendors and Outcomes of the Five Forces Analysis by 2025
Mar 01, 2021 (CDN Newswire via Comtex) -- The market research report entitled Global Bi-Specific Antibodies Therapy Market Growth (Status and Outlook)...
CDN Newswire · 2d ago
Recombinant Plasma Protein Therapeutics Market 2027 | Trends, Growth Overview, Development Size and Revenue Forecast | ARC
pune, India, Fri, 19 Feb 2021 02:50:41 / Comserve Inc. / -- The global Recombinant Plasma Protein Therapeutics market is expected to grow at noteworthy CAGR...
Comserve · 02/19 07:51
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10)
Benzinga · 02/10 12:34
Aptevo Confirms Receipt of Nominations and Proposal Notice
Stockholders Are Not Required to Take Any Action at this TimeSEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its ...
ACCESSWIRE · 02/10 00:30
BRIEF-Tang Capital Partners Says Submitted Two Director Nominees And Advisory Proposal For Consideration At Aptevo Therapeutics’ 2021 Annual Meeting
reuters.com · 02/09 14:08
Hemophilia Drugs Market Outlook By Industry Size, Share, Revenue, Regions And Top Key Players Analysis From 2020-2028
Jan 28, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Hemophillia A Drugs Market: Global Demand Analysis & Opportunity Outlook...
AmericaNewsHour · 01/28 09:30
Haemophilia Treatment Market 2021 Global impact of COVID-19 on Industry Overview By Size, Share, Trends, Growth Factors, Historical Analysis, Opportunities and Industry Segments Poised for Rapid Growth by 2025
Jan 22, 2021 (The Expresswire) -- Global "Haemophilia Treatment Market" (2021) thoroughly scrutinizes the effects of a wide range of factors impacting the...
The Express Wire · 01/22 08:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APVO stock price target is 65.67 with a high estimate of 69.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 5.64M
% Owned: 136.07%
Shares Outstanding: 4.15M
TypeInstitutionsShares
Increased
6
139.25K
New
27
2.24M
Decreased
5
126.62K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About APVO
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.